Dual HER2 blockade significantly extends progression-free survival
Thursday, December 8, 2011 - 04:00
in Health & Medicine
Adding pertuzumab to a combination of trastuzumab and docetaxel chemotherapy extended progression-free survival by a median of 6.1 months in patients with metastatic HER2-positive breast cancer compared with patients who received the combination therapy with placebo.
